64 results about "Fibrin sealants" patented technology

An external mixer assembly is provided which externally mixes and delivers a first and a second component of a biological adhesive to tissues or organs for sealing wounds, stopping bleeding and the like. The first and second components are mixed immediately after exiting from separate outlet ports disposed in fluid communication with component reservoirs. In on embodiment, the external mixer assembly includes a housing having a housing head for enclosing therein a first reservoir containing the first component, and a second reservoir containing the second component. The housing further includes a discharge nozzle defining a longitudinal axis for enclosing therein a conduit assembly having a first and a second conduit in communication with the first and second reservoir, respectively. A deflector assembly is connected to the discharge nozzle. The deflector assembly includes a deflector plate to provide a space for initial mixing of the first and second components. The deflector plate is oriented in generally parallel juxtaposed relation distal to the distal face of the discharge nozzle. The first and second components are preferably fibrinogen and thrombin which intermix to form a fibrin sealant.

Methods and compositions are provided for preparing protein concentrates from protein comprising aqueous compositions. In the subject methods, an initial protein comprising aqueous compositions, such as whole blood or a derivative thereof, is contacted with a non-protein denaturant hydrogel under conditions sufficient for a substantial amount of water present in the composition to be absorbed by the hydrogel, resulting in the production of a protein concentrate, such as a fibrinogen rich composition. Of particularl interest is the use of the subject methods to prepare fibrinogen rich compositions, where such compositions produced according to the subject invention are useful in fibrin sealants, drug delivery vehicles and in a number of other diverse applications.

This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, antiinflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant dressing.

Apparatus for delivering biologic sealant device that includes a pressure monitor coupled to the delivery device to measure pressure within the device. A method of treating a disc using the device as well as a kit including the device is described.

The invention is directed to fibrin materials for use in fibrin compositions and methods that avoid the need to use thrombin as an activating agent for fibrin monomer-based sealants. The invention provides for substantially pure fibrin chains, fibrin chain precursors, fibrin chains with other N-terminal extensions, fibrin monomer, fibrin-homolog and fibrin-analog. The invention further provides for variant fibrin .gamma.-chains. The variant gamma-chain contains one or more mutations and/or deletions in the C-terminal region following the coiled-coil forming region such that, when incorporated into fibrin-homolog, the homolog lacks the ability to self-polymerize but has the ability to form non-covalent bonds, and thereby form mixed polymers useful as sealants, with fibrinogen. The invention also provides nucleotide sequences encoding fibrin chains or fibrin chain variants and cells expressing fibrin chains, fibrin chain variants, fibrin monomer, fibrin precursor or fibrinogen-analog. The invention further provides a method of forming fibrin-related proteins in vitro from their component fibrin chains. The invention additionally provides a method for forming a fibrin sealant by a reacting a first fibrin-related protein that is incapable of self-polymerizing with a second fibrin-related protein that is incapable of self-polymerizing. Fibrin chains produced by methods of the present invention may be used as sources of substantially pure starting material for the production of important fibrin-derived factors that regulate angiogenesis, platelet aggregation, and other physiological processes.

Techniques for treating visceral or parietal membrane and tissue defects include the application of a collagen biomatrix to the defect to repair and regenerate a visceral or parietal membrane, for example in patients suffering tissue defects or undergoing visceral or parietal surgical treatment. Such approaches avoid persistent tissue leaks and their consequences such as fluid leaks and air leaks. The use of collagen biomatrix, optionally in conjunction with a fibrin sealant, an anti-adhesive, or both, can minimize tissue leaks or fluid leaks in injured patients suffering tissue defects or subjects undergoing surgery such as visceral or parietal resections and other operations.

ClotFoam is a surgical sealant and hemostatic agent designed to be used in cases of non-compressible hemorrhage. It can be applied in the operating room through laparoscopic ports, or directly over lacerated tissue in laparotomy procedures or outside the operating room through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade.

The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue .

Surgical methods of and kits for applying and stabilizing a mass of fibrin sealant or platelet concentrate at the site of surgical attachment of an implantable medical device to effect hemostasis to stem internal bleeding at the site of surgical attachment are disclosed. A mass of fibrin sealant or platelet concentrate is applied onto a porous fabric, whereby the mass is supported in the interstices or pores of the fabric, and the supported mass is applied against the site of high pressure blood leakage. The supported mass achieves hemostasis as it does not wash away from the site. The present invention is particularly useful to effect hemostasis at sutures and suture holes extending through thin-walled tissue valves and grafts when such tissue valves or grafts are sutured in place, particularly at high blood pressure sites as at the valve annulus of the aortic valve or the aorta.

The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention.

ClotFoam is an hemostatic agent designed for non-compressible hemorrhage. It can be applied outside the operating room through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used in the operating room for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue .

The present invention relates to a dry powder fibrin sealant which comprises a mixture of fibrinogen and thrombin for use in surgery, trauma and other wounds or injuries. It further relates to novel formulations comprising said dry powder fibrin sealant for use in the treatment of wounds or for surgical intervention or as a topical hemostat.

The present invention relates to a tissue sealant in which collagen and fibrin are mixed and to a method for preparing same. To this end, the method of the present invention comprises the steps of: mixing a first material using fibrinogen and aprotinin; mixing a second material using thrombin, calcium chloride, and collagen; and preparing a third material by mixing the first material and the second material. The tissue sealant prepared by the method may supplement weaknesses, i.e. strength and degradability, of the fibrin sealant which is currently available in the commercial marketplace. Further, the tissue sealant of the present invention is cytophilic and activates blood platelets contained in blood so as to induce tissue regeneration. Thus, quality and reliability of products can be significantly improved so as to satisfy various needs of consumers who are users, thereby presenting good image.

The invention relates to methods for the treatment of urinary incontinence (UI) and stress urinary incontinence (SUI) in both men and women by replacement of a damaged, absent or injured pubo-urethral ligament (PUL) via a simple injection of “Regenerative Glue.” For example, in the case of UI, the injection of “Regenerative Glue” at the PUL site will adhere the ventral surface of the urethra to the dorsal surface of the symphysis pubis (i.e. the space of Retzius), and further provide regenerative material for continuous replacement of deficient tissues and cells. “The Regenerative Glue” can be made from several commercially available materials including biocompatible glues, fibrin sealant or biocompatible gels; combined with Meschencymal stem cells (MSC) derived from bone marrow or adipose tissues.

The invention discloses a safe and efficient freeze-dried fibrin sealant and a preparation method thereof. The freeze-dried fibrin sealant is composed of independent components in the following parts by weight: 12-15 parts of freeze-dried fibrinogen powder , 3 to 5 parts of freeze-dried thrombin powder. The invention provides a freeze-dried fibrin sealing agent that can be treated by a heat-resistant method by adopting an effective fibrinogen and thrombin stabilizer and a reasonable formula. The heat treatment of the preparation can not only ensure the inactivation of lipid-enveloped and non-lipid-enveloped viruses, but also allow the preparation to be quickly reconstituted at room temperature, which greatly facilitates clinical use, especially for fibrin glue used in first aid. significance.

The invention provides a fibrin sealant which comprises a fibrin polymer and a thrombin-like enzyme, wherein a ratio of the thrombin-like enzyme to the fibrin polymer is 0.01 to 100 IU:1 mg. The fibrin sealant can be used on the aspects of hemostasis, healing promotion, defect enclosing, bonding prevention, tendon suture fixation tendon injury, molding repair of bony defect, regeneration of skin tissue, carrier slow release and the like.